1112 ET - BioNTech expects its Covid-19 booster sales to stay relatively stable even if the government narrows its recommendations of who needs the shot. The Centers for Disease Control is scheduled to vote in June on a new recommendation for who should get the Covid-19 booster, which could narrow it to high-risk groups only. BioNTech, which rose to prominence for its partnership with Pfizer during the Covid-19 pandemic, says during an analyst call that many of the people still getting the booster are in high-risk groups already. The majority of Covid vaccines in the U.S. are going to people who are older than 65 or immunocompromised, which accounts for about 20% of Americans, management says. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
May 05, 2025 11:13 ET (15:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.